Related Experiment Video
Updated: May 9, 2026
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Immune alterations in malignant melanoma and current immunotherapy concepts
Alexei Shimanovsky1, Ashif Jethava, Constantin A Dasanu
1University of Connecticut Health Science Center, Department of Medicine , Farmington, 21 Temple Street # 501, Hartford, CT 06103 , USA shimanovsky@resident.uchc.edu.
Expert Opinion on Biological Therapy
|August 13, 2013
Summary
Malignant melanoma alters the immune system, causing defects that suppress anti-tumor responses. Immunotherapy, including ipilimumab and novel agents targeting PD-1, offers promising treatment strategies for melanoma patients.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Malignant melanoma is an aggressive, immunogenic cancer.
- Melanoma induces immune defects and cytokine abnormalities, suppressing anti-tumor immunity.
- Understanding these immune alterations is key to developing innovative treatments.
Purpose of the Study:
- To comprehensively review immune abnormalities in melanoma patients.
- To summarize current and investigational melanoma immunotherapy agents.
- To highlight advancements in anti-melanoma treatment strategies.
Main Methods:
- Literature review of immune abnormalities in melanoma.
- Comprehensive summary of approved and clinical trial immunotherapy agents for melanoma.
- Analysis of novel immunomodulating agents and combination therapies.
Main Results:
- Ipilimumab (anti-CTLA-4) is a leading immunotherapy for malignant melanoma.
- Novel agents like anti-PD-1 and anti-PD-1 ligand antibodies show significant activity.
- Combination therapies are under investigation to enhance anti-melanoma effects.
Conclusions:
- Immunotherapy represents a significant advancement in malignant melanoma treatment.
- Targeting CTLA-4 and PD-1 pathways offers effective therapeutic options.
- Future research focuses on combination immunotherapies for improved patient outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...